RxDoctor Payments DataLook up a doctor →

Yvonne Smallwood-Sherrer, MD

Rheumatology · Ft. Lauderdale, FLNPI 1316940810

Payments from drug & device makers

$1,536,225in general payments, 2019–2025

Across 777 payments — averaging $1977.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$791K
  • Amgen$383K
  • Janssen Research & Development, LLC$79K
  • Pfizer$32K
  • E.r. Squibb & Sons, L.L.C.$31K
  • Bristol Myers Squibb$24K
  • plus $196K from 38 others
$7,022in research payments, 2019–2025

Across 14 payments — averaging $501.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$4K
  • Sanofi US Services Inc.$2K
  • GSK$2K

What the payments were for

  • Consulting fees$19,42021%
  • Speaking & faculty fees$43,44847%
  • Grants$2400%
  • Travel & lodging$12,80414%
  • Food & beverage$16,25918%
  • Education$3460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,536,225 in reported general payments places this provider in the 95th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$310,577
Medicare patients
112
Services billed
20,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast23$110,266
Xeljanz XrTofacitinib Citrate13$87,267
ForteoTeriparatide16$75,118
Cimzia (2 Pack)Certolizumab Pegol11$61,189
ActemraTocilizumab12$54,824
ProliaDenosumab12$20,471
Hydroxychloroquine Sulfate68$2,269
MethotrexateMethotrexate Sodium63$1,185
Mycophenolate Mofetil25$885
Prednisone73$460
Methylprednisolone15$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia$382,582$130,73735 claims
Lilly USA, LLCForteo$466$75,11816 claims
UCB, Inc.Cimzia (2 Pack)$5,638$61,18911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Ft. Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →